Scholarlink

<p>Degeneration of substantia nigra pars compacta dopaminergic neurons is the “hallmark” of Parkinson’s disease (PD) and is responsible for motor signs. Other neurotransmitter systems are responsible for non-motor symptoms that may precede by decades the clinical onset of motor symptoms. The pathophysiology is complex and neurodegeneration involves excitotoxicity mechanisms and neuroinflammation. L-DOPA is the “gold” symptomatic therapy but does not halt the progression of the disease. Therefore, neuroprotective strategies are highly demanded. Metabotropic glutamate (mGlu) receptors have emerged as potential pharmacological targets because they modulate glutamatergic, GABAergic, and dopaminergic neurotransmissions, and have been implicated in mechanisms of neurodegeneration and neuroinflammation. Thus, mGlu receptors represent valuable targets for the development of new disease-modifying and symptomatic therapies for PD. This review highlights the role of individual mGlu receptor subtypes in the pathophysiology of motor and non-motor symptoms of PD and in mechanisms that contribute to the progression of the disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月10日

查看全文
  • Marika Alborghetti,
  • Alessia Ceccherelli,
  • Matteo Caridi,
  • Ferdinando Nicoletti,
  • Giuseppe Battaglia,
  • Valeria Bruno

摘要

Degeneration of substantia nigra pars compacta dopaminergic neurons is the “hallmark” of Parkinson’s disease (PD) and is responsible for motor signs. Other neurotransmitter systems are responsible for non-motor symptoms that may precede by decades the clinical onset of motor symptoms. The pathophysiology is complex and neurodegeneration involves excitotoxicity mechanisms and neuroinflammation. L-DOPA is the “gold” symptomatic therapy but does not halt the progression of the disease. Therefore, neuroprotective strategies are highly demanded. Metabotropic glutamate (mGlu) receptors have emerged as potential pharmacological targets because they modulate glutamatergic, GABAergic, and dopaminergic neurotransmissions, and have been implicated in mechanisms of neurodegeneration and neuroinflammation. Thus, mGlu receptors represent valuable targets for the development of new disease-modifying and symptomatic therapies for PD. This review highlights the role of individual mGlu receptor subtypes in the pathophysiology of motor and non-motor symptoms of PD and in mechanisms that contribute to the progression of the disease.